Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15707223 | 0.85 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL20306595 | 0.82 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL20299983 | 0.78 | DGAT1 (0.44) | DGAT1 | |
| SCHEMBL20301484 | 0.78 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL25120640 | 0.78 | NR1H3 (0.43) | DGAT1 | |
| SCHEMBL25911958 | 0.77 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL20301731 | 0.77 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL23063088 | 0.77 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL31267051 | 0.77 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL23063108 | 0.75 | DGAT1 (0.33) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4499656-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119183453-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| EP-4295852-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023192960-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | DGAT1 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.